{
  "interactions": [
    {
      "id": "int_001",
      "drug_a": "NSAIDs",
      "drug_a_group": "NSAIDs",
      "drug_b": "Warfarin",
      "drug_b_group": "anticoagulants",
      "severity": "major",
      "mechanism": "pharmacodynamic",
      "description": "NSAIDs increase the risk of bleeding when used with warfarin by inhibiting platelet function and potentially displacing warfarin from protein binding sites.",
      "clinical_effects": ["Increased bleeding risk", "GI hemorrhage", "Prolonged INR"],
      "symptoms": ["Easy bruising", "Prolonged bleeding", "Blood in urine or stool", "Nosebleeds"],
      "recommendation": "Avoid combination if possible. If necessary, use lowest effective NSAID dose for shortest duration and monitor INR closely.",
      "alternatives": ["Paracetamol for pain relief", "Topical NSAIDs"],
      "monitoring": "Monitor INR frequently, watch for signs of bleeding",
      "evidence_level": "high",
      "references": ["Drug Interaction Facts 2024", "Lexicomp"]
    },
    {
      "id": "int_002",
      "drug_a": "metronidazole",
      "drug_a_group": "antibiotics",
      "drug_b": "alcohol",
      "drug_b_group": "alcohol_interaction",
      "severity": "contraindicated",
      "mechanism": "pharmacokinetic",
      "description": "Metronidazole inhibits aldehyde dehydrogenase, causing accumulation of acetaldehyde when alcohol is consumed, leading to severe disulfiram-like reaction.",
      "clinical_effects": ["Severe nausea and vomiting", "Flushing", "Tachycardia", "Hypotension"],
      "symptoms": ["Intense nausea", "Facial flushing", "Rapid heartbeat", "Severe headache", "Difficulty breathing"],
      "recommendation": "Absolutely avoid alcohol during treatment and for 48 hours after completing metronidazole.",
      "alternatives": [],
      "monitoring": "Educate patient about alcohol avoidance",
      "evidence_level": "high",
      "references": ["British National Formulary", "UpToDate"]
    },
    {
      "id": "int_003",
      "drug_a": "statins",
      "drug_a_group": "statins",
      "drug_b": "macrolides",
      "drug_b_group": "antibiotics",
      "severity": "major",
      "mechanism": "pharmacokinetic",
      "description": "Macrolide antibiotics (especially clarithromycin and erythromycin) inhibit CYP3A4, increasing statin levels and risk of myopathy/rhabdomyolysis.",
      "clinical_effects": ["Myopathy", "Rhabdomyolysis", "Elevated CK levels", "Acute kidney injury"],
      "symptoms": ["Muscle pain", "Muscle weakness", "Dark urine", "Fatigue"],
      "recommendation": "Temporarily stop statin during macrolide course, or use azithromycin which has less CYP3A4 interaction.",
      "alternatives": ["Azithromycin instead of clarithromycin", "Pause statin temporarily"],
      "monitoring": "Monitor for muscle symptoms, check CK if symptoms occur",
      "evidence_level": "high",
      "references": ["FDA Drug Safety Communication", "Lexicomp"]
    },
    {
      "id": "int_004",
      "drug_a": "benzodiazepines",
      "drug_a_group": "CNS_depressants",
      "drug_b": "opioids",
      "drug_b_group": "CNS_depressants",
      "severity": "contraindicated",
      "mechanism": "pharmacodynamic",
      "description": "Combined CNS depression from benzodiazepines and opioids significantly increases risk of respiratory depression, sedation, coma, and death.",
      "clinical_effects": ["Severe respiratory depression", "Profound sedation", "Coma", "Death"],
      "symptoms": ["Extreme drowsiness", "Confusion", "Slow/shallow breathing", "Unresponsiveness"],
      "recommendation": "Avoid concurrent use. If absolutely necessary, use lowest doses and monitor closely.",
      "alternatives": ["Non-opioid analgesics", "Non-benzodiazepine anxiolytics"],
      "monitoring": "Close monitoring in medical setting, have naloxone available",
      "evidence_level": "high",
      "references": ["FDA Boxed Warning", "CDC Guidelines"]
    },
    {
      "id": "int_005",
      "drug_a": "ACE_inhibitors",
      "drug_a_group": "cardiovascular",
      "drug_b": "potassium_supplements",
      "drug_b_group": "supplements",
      "severity": "major",
      "mechanism": "pharmacodynamic",
      "description": "ACE inhibitors reduce aldosterone secretion, decreasing potassium excretion. Combined with potassium supplements, this can cause dangerous hyperkalemia.",
      "clinical_effects": ["Hyperkalemia", "Cardiac arrhythmias", "Muscle weakness"],
      "symptoms": ["Muscle weakness", "Irregular heartbeat", "Nausea", "Numbness/tingling"],
      "recommendation": "Avoid routine potassium supplementation with ACE inhibitors. Monitor potassium levels if supplement is necessary.",
      "alternatives": ["Dietary potassium from food is usually sufficient"],
      "monitoring": "Regular serum potassium monitoring",
      "evidence_level": "high",
      "references": ["UpToDate", "American Heart Association Guidelines"]
    },
    {
      "id": "int_006",
      "drug_a": "NSAIDs",
      "drug_a_group": "NSAIDs",
      "drug_b": "NSAIDs",
      "drug_b_group": "NSAIDs",
      "severity": "major",
      "mechanism": "additive",
      "description": "Using multiple NSAIDs together significantly increases the risk of GI bleeding, kidney damage, and cardiovascular events without additional pain relief.",
      "clinical_effects": ["GI bleeding", "Peptic ulcers", "Acute kidney injury", "Cardiovascular events"],
      "symptoms": ["Stomach pain", "Black tarry stools", "Blood in vomit", "Reduced urine output"],
      "recommendation": "Never use more than one NSAID at a time. If one NSAID is insufficient, consider alternative pain management.",
      "alternatives": ["Paracetamol", "Add a PPI for gastroprotection"],
      "monitoring": "Monitor for GI symptoms, renal function",
      "evidence_level": "high",
      "references": ["FDA Drug Safety Communication", "British National Formulary"]
    },
    {
      "id": "int_007",
      "drug_a": "beta_blockers",
      "drug_a_group": "cardiovascular",
      "drug_b": "calcium_channel_blockers",
      "drug_b_group": "cardiovascular",
      "severity": "moderate",
      "mechanism": "pharmacodynamic",
      "description": "Both drug classes decrease heart rate and contractility. Combination may cause severe bradycardia, heart block, or hypotension.",
      "clinical_effects": ["Severe bradycardia", "Heart block", "Hypotension", "Heart failure exacerbation"],
      "symptoms": ["Very slow pulse", "Dizziness", "Fainting", "Shortness of breath"],
      "recommendation": "Use combination with caution. Monitor heart rate and blood pressure closely. Avoid verapamil/diltiazem with beta blockers.",
      "alternatives": ["Dihydropyridine CCBs (amlodipine) are safer with beta blockers"],
      "monitoring": "Regular ECG monitoring, blood pressure, heart rate",
      "evidence_level": "high",
      "references": ["ACC/AHA Guidelines", "Drug Interaction Facts"]
    },
    {
      "id": "int_008",
      "drug_a": "PPIs",
      "drug_a_group": "gastrointestinal",
      "drug_b": "clopidogrel",
      "drug_b_group": "antiplatelet",
      "severity": "moderate",
      "mechanism": "pharmacokinetic",
      "description": "Some PPIs (especially omeprazole and esomeprazole) inhibit CYP2C19, reducing conversion of clopidogrel to its active metabolite and decreasing antiplatelet effect.",
      "clinical_effects": ["Reduced antiplatelet efficacy", "Increased cardiovascular events", "Stent thrombosis risk"],
      "symptoms": ["May be asymptomatic until cardiovascular event occurs"],
      "recommendation": "Use pantoprazole or rabeprazole instead of omeprazole/esomeprazole. Consider H2 blockers if PPI not essential.",
      "alternatives": ["Pantoprazole", "Rabeprazole", "Famotidine"],
      "monitoring": "Clinical monitoring for cardiovascular events",
      "evidence_level": "moderate",
      "references": ["FDA Drug Safety Communication", "European Medicines Agency"]
    },
    {
      "id": "int_009",
      "drug_a": "fluoroquinolones",
      "drug_a_group": "antibiotics",
      "drug_b": "NSAIDs",
      "drug_b_group": "NSAIDs",
      "severity": "moderate",
      "mechanism": "pharmacodynamic",
      "description": "Fluoroquinolones can lower seizure threshold. NSAIDs may enhance this effect, increasing risk of CNS stimulation and seizures.",
      "clinical_effects": ["Seizures", "CNS stimulation", "Confusion"],
      "symptoms": ["Seizures", "Tremor", "Restlessness", "Confusion"],
      "recommendation": "Use alternative pain relief during fluoroquinolone therapy. Use with caution in patients with seizure history.",
      "alternatives": ["Paracetamol for pain relief"],
      "monitoring": "Monitor for CNS symptoms, especially in patients with seizure history",
      "evidence_level": "moderate",
      "references": ["Lexicomp", "Drug Interaction Facts"]
    },
    {
      "id": "int_010",
      "drug_a": "penicillins",
      "drug_a_group": "antibiotics",
      "drug_b": "methotrexate",
      "drug_b_group": "immunosuppressants",
      "severity": "major",
      "mechanism": "pharmacokinetic",
      "description": "Penicillins reduce renal excretion of methotrexate, potentially leading to toxic methotrexate levels.",
      "clinical_effects": ["Methotrexate toxicity", "Bone marrow suppression", "Hepatotoxicity", "Nephrotoxicity"],
      "symptoms": ["Mouth sores", "Easy bruising", "Fatigue", "Yellow skin", "Reduced urine output"],
      "recommendation": "Monitor methotrexate levels closely. Consider alternative antibiotics. May need methotrexate dose reduction.",
      "alternatives": ["Azithromycin", "Fluoroquinolones (with caution)"],
      "monitoring": "Methotrexate levels, complete blood count, liver and kidney function",
      "evidence_level": "high",
      "references": ["UpToDate", "Lexicomp"]
    },
    {
      "id": "int_011",
      "drug_a": "SSRIs",
      "drug_a_group": "antidepressants",
      "drug_b": "NSAIDs",
      "drug_b_group": "NSAIDs",
      "severity": "moderate",
      "mechanism": "pharmacodynamic",
      "description": "SSRIs inhibit serotonin uptake by platelets, impairing platelet aggregation. Combined with NSAIDs, this significantly increases bleeding risk.",
      "clinical_effects": ["GI bleeding", "Easy bruising", "Prolonged bleeding"],
      "symptoms": ["Black tarry stools", "Blood in vomit", "Easy bruising", "Prolonged bleeding from cuts"],
      "recommendation": "Use paracetamol instead of NSAIDs when possible. If NSAID necessary, add gastroprotection with PPI.",
      "alternatives": ["Paracetamol", "Add PPI if NSAID needed"],
      "monitoring": "Monitor for signs of GI bleeding",
      "evidence_level": "high",
      "references": ["BMJ Best Practice", "Lexicomp"]
    },
    {
      "id": "int_012",
      "drug_a": "benzodiazepines",
      "drug_a_group": "sedatives",
      "drug_b": "alcohol",
      "drug_b_group": "alcohol_interaction",
      "severity": "major",
      "mechanism": "pharmacodynamic",
      "description": "Both benzodiazepines and alcohol are CNS depressants. Combined use can cause severe sedation, respiratory depression, and death.",
      "clinical_effects": ["Severe CNS depression", "Respiratory depression", "Coma", "Death"],
      "symptoms": ["Extreme drowsiness", "Slurred speech", "Impaired coordination", "Slow breathing", "Unresponsiveness"],
      "recommendation": "Avoid alcohol completely while taking benzodiazepines.",
      "alternatives": [],
      "monitoring": "Educate patient about alcohol avoidance",
      "evidence_level": "high",
      "references": ["FDA Warning", "All benzodiazepine prescribing information"]
    },
    {
      "id": "int_013",
      "drug_a": "bronchodilators",
      "drug_a_group": "beta_agonists",
      "drug_b": "beta_blockers",
      "drug_b_group": "cardiovascular",
      "severity": "major",
      "mechanism": "antagonistic",
      "description": "Beta blockers antagonize the bronchodilator effects of beta-agonists and may precipitate bronchospasm, especially in asthmatics.",
      "clinical_effects": ["Bronchospasm", "Reduced bronchodilator efficacy", "Asthma exacerbation"],
      "symptoms": ["Wheezing", "Shortness of breath", "Chest tightness", "Coughing"],
      "recommendation": "Avoid non-selective beta blockers in asthma patients. Use cardioselective beta blockers (bisoprolol, metoprolol) at lowest effective dose if necessary.",
      "alternatives": ["Cardioselective beta blockers", "Alternative antihypertensives"],
      "monitoring": "Monitor respiratory function",
      "evidence_level": "high",
      "references": ["GINA Guidelines", "British Thoracic Society"]
    },
    {
      "id": "int_014",
      "drug_a": "painkillers",
      "drug_a_group": "painkillers",
      "drug_b": "painkillers",
      "drug_b_group": "painkillers",
      "severity": "moderate",
      "mechanism": "additive",
      "description": "Using multiple paracetamol-containing products can lead to unintentional overdose and severe liver damage.",
      "clinical_effects": ["Hepatotoxicity", "Liver failure", "Death"],
      "symptoms": ["Nausea", "Vomiting", "Abdominal pain", "Jaundice", "Confusion"],
      "recommendation": "Check all medications for paracetamol content. Do not exceed 4g paracetamol daily from all sources.",
      "alternatives": ["Single paracetamol product at appropriate dose"],
      "monitoring": "Total daily paracetamol intake, liver function if overdose suspected",
      "evidence_level": "high",
      "references": ["FDA Drug Safety Communication", "Poison Control Guidelines"]
    },
    {
      "id": "int_015",
      "drug_a": "cephalosporins",
      "drug_a_group": "antibiotics",
      "drug_b": "aminoglycosides",
      "drug_b_group": "antibiotics",
      "severity": "moderate",
      "mechanism": "additive",
      "description": "Both drug classes can cause nephrotoxicity. Combined use increases the risk of acute kidney injury.",
      "clinical_effects": ["Nephrotoxicity", "Acute kidney injury"],
      "symptoms": ["Decreased urine output", "Swelling", "Fatigue", "Confusion"],
      "recommendation": "If combination necessary, ensure adequate hydration and monitor renal function closely.",
      "alternatives": ["Consider alternative antibiotic combinations"],
      "monitoring": "Daily renal function tests, maintain adequate hydration",
      "evidence_level": "high",
      "references": ["UpToDate", "Sanford Guide to Antimicrobial Therapy"]
    }
  ],
  "safe_combinations": [
    {
      "drug_a": "Paracetamol",
      "drug_b": "PPIs",
      "note": "Generally safe combination"
    },
    {
      "drug_a": "Amlodipine",
      "drug_b": "Statins",
      "note": "Safe and often used together for cardiovascular protection"
    },
    {
      "drug_a": "Azithromycin",
      "drug_b": "PPIs",
      "note": "Safe combination, minimal interaction"
    }
  ]
}
